Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rib-X Pharmaceuticals, a development-stage company engaged in the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, has received a key antibiotic patent in China.
Subscribe to our email newsletter
The State Intellectual Property Office of the People’s Republic of China has issued a new Chinese patent which provides composition of matter protection for Rib-X’s novel oxazolidinone antibiotic, radezolid.
Rib-X has established a broad patent portfolio related to radezolid, including the issuance of composition of matter for radezolid in the US. The company anticipates issuance of additional patents in all major and emerging markets.
Susan Froshauer, president and CEO of Rib-X Pharmaceuticals, said: “This Chinese patent strengthens Rib-X’s existing intellectual property portfolio and underscores our ability to successfully design and develop antibiotics that overcome resistant bacteria.
“China is the world’s largest emerging pharmaceutical market, and the issuance of this patent enhances Rib-X’s commercial opportunities in this important region of the world.”